Get started
Author

Loipa Medel Pérez

Observed names: Loipa Medel, Loipa Medel Perez, Medel Pérez, Loipa
ORCID: 0000-0002-7587-3119
Observed ORCID: 0000-0002-7587-3119
OpenAlex ID: A5003548949
Blocking Egfr with Nimotuzumab: A Novel Strategy for Covid-19 Treatment
2022 · Henrry Diaz Londres, Jorge Jiménez Armada, et al. · Immunotherapy · 43
PDF
Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
2022 · Danay Saavedra, Ana L. Añé-Kourí, et al. · Immunology Letters · 13
PDF
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
2022 · Henrry Diaz, Jorge Jiménez, et al. · Frontiers in Public Health · 3
PDF
Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
2025 · Sailyn Alfonso Alemán, Haslen Cáceres Lavernia, et al. · Vaccines · 2
PDF
Targeting CD6 in solid tumors: safety, early efficacy, and mechanistic insights from a proof-of-concept trial of itolizumab
2026 · Cynthia González Muñoz, Raiza Ruiz-Lorente, et al. · Journal for ImmunoTherapy of Cancer
PDF
PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD Patients
2024 · Jenysbel de la C. Hernandez Reyes, Orestes Santos Morales, et al. · Vaccines
PDF
Reposicionamiento del anticuerpo monoclonal humanizado cubano nimotuzumab en el tratamiento de pacientes con COVID-19
2023 · Díaz Londres, Henrry, Jiménez Armada, Jorge, et al. · Anales de la Academia de Ciencias de Cuba
PDF
Works count: 7
Citation count: 61
H-index: 3
I10-index: 2
Year
Topic
Type